Polyomavirus nephropathy has become an important complication in kidney transplantation, with a prevalence of 1% to 8%. Unfortunately, the risk factors for polyomavirus nephropathy and renal allograft loss are not well defined. The definitive diagnosis is made through assessment of a kidney transplant biopsy. Recently, noninvasive urine and serum markers have been used to assist in polyomavirus nephropathy diagnosis and monitoring. Primary treatment is immunosuppression reduction, but must be balanced with the risks of rejection. No antiviral treatments for polyomavirus nephropathy have been approved by the Food and Drug Administration. Although cidofovir has shown in vitro activity against murine polyomaviruses, and has been effective in some patients, it is associated with significant nephrotoxicity. Graft loss due to polyomavirus nephropathy should not be a contraindication to retransplantation; however, experience is limited. This review presents potential risk factors, screening, diagnostic and monitoring methods, therapeutic management, and retransplantation experience for polyomavirus nephropathy.
VilchezRAKozinetzCAArringtonASMaddenCRButelJS. Simian virus 40 in human cancers. Am J Med.2003; 114:675–684.
9.
Barbanti-BrodanoGMartiniFDe MatteiMLazzarinLCoralliniATognonM. BK and JC human polyomaviruses and simian virus 40: Natural history of infection in humans, experimental oncogenicity, and association with human tumors. Adv Virus Res.1998;50:69–99.
10.
LeeWLanghoffE. Polyomavirus and Human Cancer. Graft.2002;5(suppl):S73–S9.
11.
ImperialeMJ. The human polyomaviruses, BKV and JCV: Molecular pathogenesis of acute disease and potential role in cancer. Virology. February 2000;267:1–7.
12.
KhaliliK. Human neurotropic JC virus and its association with brain tumors. Dis Markers.2001;17:143–147.
13.
BoldoriniRPaganiECarPG. Molecular characterisation of JC virus strains detected in human brain tumours. Pathology.2003;35:248–253.
14.
Del ValleLGordonJEnamS. Expression of human neurotropic polyomavirus JCV late gene product agnoprotein in human medulloblastoma. J Natl Cancer Inst.2002;94:267–273.
15.
DorriesKLoeberGMeixensbergerJ. Association of polyomaviruses JC, SV40, and BK with human brain tumors. Virology.1987;160:268–270.
16.
ButelJSLednickyJA. Cell and molecular biology of simian virus 40: Implications for human infections and disease. J Natl Cancer Inst.1999;91:119–134.
17.
MortimerEAJrLepowMLGoldERobbinsFCBurtonGJFraumeniJFJr.Long-term follow-up of persons inadvertently inoculated with SV40 as neonates. N Engl J Med.1981;305:1517–1518.
18.
LiRMMannonRBKleinerD. BK virus and SV40 co-infection in polyomavirus nephropathy. Transplantation.2002;74:1497–1504.
19.
PadgettBLWalkerDLZuRheinGMEckroadeRJDesselBH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet.1971;1:1257–1260.
20.
GardnerSDFieldAMColemanDVHulmeB. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet.1971;1:1253–1257.
21.
MajorEO. Human polyomavirus. In: KnipeDM HPGriffinDE, eds. Fields Virology.4th ed.Philadelphia, Pa: Lippincott Williams and Wilkins; 2001:2175–2196.
22.
AndrewsCAShahKVDanielRWHirschMSRubinRH. A serological investigation of BK virus and JC virus infections in recipients of renal allografts. J Infect Dis.1988;158:176–181.
23.
DuboisVDutroncHLafonME. Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol.1997; 35:2288–2292.
24.
RileyDTothCPergolaP. Simultaneous manifestations of polyoma BK virus infection in two patients with kidney transplants from the same cadaver donor [abstract]. J Am Soc Nephrol.1999;10:764.
25.
BergerJR. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: Explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neurovirol.2003;9(suppl 1):38–41.
26.
SethPDiazFMajorEO. Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy. J Neurovirol.2003;9:236–246.
27.
RandhawaPBakshFAokiNTschirhartDFinkelsteinS. JC virus infection in allograft kidneys: Analysis by polymerase chain reaction and immunohistochemistry. Transplantation.2001;71:1300–1303.
28.
TrofeJCavalloTFirstMR. Polyomavirus in kidney and kidney-pancreas transplantation: A defined protocol for immunosuppression reduction and histologic monitoring. Transplant Proc.2002;34:1788–1789.
29.
BoldoriniROmodeo-ZoriniENebuloniM. Lytic JC virus infection in the kidneys of AIDS subjects. Mod Pathol. January 2003;16:35–42.
30.
AtwoodWJNorkinLC. Class I major histocompatibility proteins as cell surface receptors for simian virus 40. J Virol.1989;63:4474–4477.
31.
BreauWCAtwoodWJNorkinLC. Class I major histocompatibility proteins are an essential component of the simian virus 40 receptor. J Virol.1992;66:2037–2045.
32.
TsaiBGilbertJMStehleTLencerWBenjaminTLRapoportTA. Gangliosides are receptors for murine polyoma virus and SV40. Embo J.2003;22:4346–4355.
33.
LiuCKHopeAPAtwoodWJ. The human polyomavirus, JCV, does not share receptor specificity with SV40 on human glial cells. J Neurovirol. February 1998;4:49–58.
34.
LiuCKWeiGAtwoodWJ. Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2–6)-linked sialic acids. J Virol.1998;72:4643–4649.
35.
EashSTavaresRStopaEGRobbinsSHBrossayLAtwoodWJ. Differential distribution of the JC virus receptor-type sialic acid in normal human tissues. Am J Pathol.2004;164:419–428.
36.
SegantiLMastromarinoPSupertiFSinibaldiLOrsiN. Receptors for BK virus on human erythrocytes. Acta Virol.1981;25:177–181.
37.
SinibaldiLGoldoniPPietropaoloVLonghiCOrsiN. Involvement of gangliosides in the interaction between BK virus and Vero cells. Arch Virol.1990;113:291–296.
38.
SinibaldiLGoldoniPPietropaoloVCattaniLPelusoCDi TarantoC. Role of phospholipids in BK virus infection and haemagglutination. Microbiologica.1992;15:337–344.
39.
ImperialeMJ. The human polyomaviruses: An overview. In: KhaliliKStonerG, eds. Human Polyomaviruses: Molecular and Clinical Perspectives.New York. NY: Wiley-Liss; 2001:53–72.
40.
KahanAVColemanDVKossLG. Activation of human polyomavirus infection-detection by cytologic technics. Am J Clin Pathol.1980;74:326–332.
41.
ColemanDVWolfendaleMRDanielRA. A prospective study of human polyomavirus infection in pregnancy. J Infect Dis. July 1980;142:1–8.
42.
MylonakisEGoesNRubinRHCosimiABColvinRBFishmanJA. BK virus in solid organ transplant recipients: An emerging syndrome. Transplantation.2001;72:1587–1592.
43.
SafakMKhaliliK. An overview: Human polyomavirus JC virus and its associated disorders. J Neurovirol.2003;9(suppl 1):3–9.
44.
BinetINickeleitVHirschH. Polyomavirus infections in transplant recipients. Curr Opin Organ Transplant.2000; 5:210–216.
45.
ColemanDVMackenzieEFGardnerSDPouldingJMAmerBRussellWJ. Human polyomavirus (BK) infection and ureteric stenosis in renal allograft recipients. J Clin Pathol.1978;31:338–347.
46.
HirschHH. Polyomavirus BK nephropathy: A (re-)emerging complication in renal transplantation. Am J Transplant. January 2002;2:25–30.
47.
Petrogiannis-HaliotisTSakoulasGKirbyJ. BK-related polyomavirus vasculopathy in a renal-transplant recipient. N Engl J Med.2001;345:1250–1255.
48.
KoralnikIJDu PasquierRAKurodaMJ. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol.2002;168:499–504.
49.
Du PasquierRAKurodaMJSchmitzJE. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J Virol.2003;77:11918–11926.
50.
ReploegMDStorchGACliffordDB. Bk virus: A clinical review. Clin Infect Dis.2001;33:191–202.
51.
PahariAReesL. BK virus-associated renal problems— clinical implications. Pediatr Nephrol.2003;18:743–748.
DrachenbergCBPapadimitriouJCWaliRCubittCLRamosE. BK polyoma virus allograft nephropathy: Ultrastructural features from viral cell entry to lysis. Am J Transplant.2003;3:1383–1392.
54.
HoganTFBordenECMcBainJAPadgettBLWalkerDL. Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med.1980;92:373–378.
55.
BinetINickeleitVHirschHH. Polyomavirus disease under new immunosuppressive drugs: A cause of renal graft dysfunction and graft loss. Transplantation.1999;67:918–922.
DrachenbergCBBeskowCOCangroCB. Human polyoma virus in renal allograft biopsies: Morphological findings and correlation with urine cytology. Hum Pathol.1999;30:970–977.
58.
GinevriFDe SantisRComoliP. Polyomavirus BK infection in pediatric kidney-allograft recipients: A singlecenter analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation.2003;75:1266–1270.
59.
HowellDNSmithSRButterlyDW. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation.1999;68:1279–1288.
60.
de LignyHurault BEtienneIFrancoisA. Polyomavirus-induced acute tubulo-interstitial nephritis in renal allograft recipients. Transplant Proc.2000;32:2760–2761.
61.
LinPLVatsANGreenM. BK virus infection in renal transplant recipients. Pediatr Transplant.2001;5:398–405.
62.
MayrMNickeleitVHirschHHDickenmannMMihatschMJSteigerJ. Polyomavirus BK nephropathy in a kidney transplant recipient: Critical issues of diagnosis and management. Am J Kidney Dis. September 2001;38:E13.
63.
MengelMMarwedelMRadermacherJ. Incidence of polyomavirus-nephropathy in renal allografts: Influence of modern immunosuppressive drugs. Nephrol Dial Transplant.2003;18:1190–1196.
64.
NickeleitVHirschHHZeilerM. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant.2000;15:324–332.
65.
PappoODemetrisAJRaikowRBRandhawaPS. Human polyoma virus infection of renal allografts: Histopathologic diagnosis, clinical significance, and literature review. Mod Pathol.1996;9:105–109.
66.
RamosEDrachenbergCBPapadimitriouJC. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol.2002;13:2145–2151.
67.
RamosEDrachenbergCBPortocarreroM. BK virus nephropathy diagnosis and treatment: Experience at the University of Maryland Renal Transplant Program. Clin Transpl.2002:143–153.
68.
BarriYMAhmadIKetelBL. Polyoma viral infection in renal transplantation: The role of immunosuppressive therapy. Clin Transplant.2001;15:240–246.
69.
TrofeJGaberLWStrattaRJ. Polyomavirus in kidney and kidney-pancreas transplant recipients. Transpl Infect Dis. March 2003;5:21–28.
70.
HirschHHKnowlesWDickenmannM. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med.2002;347:488–496.
71.
RandhawaPSDemetrisAJ. Nephropathy due to polyomavirus type BK. N Engl J Med.2000;342:1361–1363.
72.
ArthurRRShahKV. Occurrence and significance of *papovaviruses BK and JC in the urine. Prog Med Virol.1989; 36:42–61.
73.
NickeleitVHirschHHBinetIF. Polyomavirus infection of renal allograft recipients: From latent infection to manifest disease. J Am Soc Nephrol.1999;10:1080–1089.
74.
MathurVSOlsonJLDarraghTMYenTS. Polyomavirus-induced interstitial nephritis in two renal transplant recipients: Case reports and review of the literature. Am J Kidney Dis.1997;29:754–758.
75.
BuehrigCKLagerDJStegallMD. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int.2003;64:665–673.
76.
RandhawaPSVatsAZygmuntD. Quantitation of viral DNA in renal allograft tissue from patients with BK virus nephropathy. Transplantation.2002;74:485–488.
77.
AghaIBrennanD. BK virus and current immunosuppressive therapy. Graft.2002;5(suppl):S65–S72.
78.
ElliABanfiGFogazziGBTarantinoAPonticelliC. BK polyomavirus interstitial nephritis in a renal transplant patient with no previous acute rejection episodes. J Nephrol.2002; 15:313–316.
79.
NickeleitVKlimkaitTBinetIF. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med.2000; 342:1309–1315.
80.
FishmanJ. BK virus nephropathy—polyomavirus adding insult to injury. N Engl J Med.2002;347:527–530.
81.
HirschHHMohauptMKlimkaitT. Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy [letters to the editor]. J Infect Dis.2001;184:1494–1495. Author reply in J Infect Dis. 2001;184:1495–1496.
82.
RandhawaPSFinkelsteinSScantleburyV. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation.1999;67:103–109.
83.
NickeleitVSteigerJMihatschMJ. BK virus infection after kidney transplantation. Graft.2002;5(suppl):S46–S57.
84.
HariharanAKlassenD. BK infection after nonrenal transplantation. Graft.2002;5(suppl):S58–S64.
85.
MasudaKAkutagawaKYutaniCKishitaHIshibashi-UedaHImakitaM. Persistent infection with human polyomavirus revealed by urinary cytology in a patient with heart transplantation. A case report. Acta Cytologica.1998; 42:803–806.
86.
PriftakisPBogdanovicGTydenGDalianisT. Polyomaviruria in renal transplant patients is not correlated to the cold ischemia period or to rejection episodes. J Clin Microbiol.2000;38:406–407.
87.
KristoffersenAKJohnsenJISeternesOMRollagHDegreMTraavikT. The human polyomavirus BK T antigen induces gene expression in human cytomegalovirus. Virus Res. November 1997;52:61–71.
88.
FusaroFMurerLBusoloFRigamontiWZanonGFZacchelloG. CMV and BKV ureteritis: Which prognosis for the renal graft?J Nephrol.2003;16:591–594.
89.
DrachenbergRCDrachenbergCBPapadimitriouJC. Morphological spectrum of polyoma virus disease in renal allografts: Diagnostic accuracy of urine cytology. Am J Transplant.2001;1:373–381.
90.
DingRMedeirosMDadhaniaD. Noninvasive diagnosis of BK virus nephritis by measurement of messenger RNA for BK virus VP1 in urine. Transplantation.2002;74:987–994.
91.
LimayeAPJeromeKRKuhrCS. Quantitation of BK virus load in serum for the diagnosis of BK virus-associated nephropathy in renal transplant recipients. J Infect Dis.2001;183:1669–1672.
92.
RandhawaPHoAVatsAShapiroRWeckK. Quantitative measurement of BK virus load in urine and plasma of renal transplant patients: Correlation with biopsy findings [abstract 855]. Am J Transplant.2003;3(suppl 5):371.
93.
CelikBShapiroRVatsARandhawaPS. Polyomavirus allograft nephropathy: Sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression. Am J Transplant.2003;3:1378–1382.
94.
AhujaMCohenEPDayerAM. Polyoma virus infection after renal transplantation. Use of immunostaining as a guide to diagnosis. Transplantation.2001;71:896–899.
95.
BoldoriniRZoriniEOViganoPNebuloniMMenaMMongaG. Cytologic and biomolecular diagnosis of polyomavirus infection in urine specimens of HIV-positive patients. Acta Cytol.2000;44:205–210.
96.
KadambiPVJosephsonMAWilliamsJ. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant.2003;3:186–191.
97.
ScantleburyVShapiroRRandhawaPWeckKVatsA. Cidofovir: A method of treatment for BK virus associated transplant nephropathy. Graft.2002;5(suppl):S82–S87.
98.
VatsAShapiroRRandhawaSingh P. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation.2003;75:105–112.
99.
VatsA. Viral load monitoring in BK virus-associated nephropathy. Nephrol News Issues.2002;(suppl):S17–S19.
100.
TrofeJGordonJRoy-ChaudhuryP. Correlation of BK viral load monitoring and host immune response in post-transplant polyomavirus nephropathy (PVN) [abstract 852]. Am J Transplant.2003;3(suppl 5):370.
101.
RoskopfJFitzsimmonsWAhsanNLaskowD. The pharmacologic treatment of human polyomavirus infection. Graft.2002;5(suppl):S88–S95.
102.
LeventhalBSoaveRMouradianJCheighJS. Renal dysfunction and hyperglycemia in a renal transplant recipient. Transpl Infect Dis.1999;1:288–294.
103.
HussainSBresnahanBACohenEPHariharanS. Rapid kidney allograft failure in patients with polyoma virus nephritis with prior treatment with antilymphocyte agents. Clin Transplant. February 2002;16:43–47.
104.
AndreiGSnoeckRVandeputteMDe ClercqE. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother.1997;41:587–593.
105.
HouJMajorEO. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol.1998;4:451–456.
106.
De LucaAGiancolaMLCingolaniA. Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. Clin Infect Dis.1999;28:624–628.
107.
HallCDDafniUSimpsonD. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med.1998;338:1345–1351.
108.
AksamitAJ. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J Neurovirol.2001;7:386–390.
109.
ChapmanCFlowerAJDurrantST. The use of vidarabine in the treatment of human polyomavirus associated acute haemorrhagic cystitis. Bone Marrow Transplant.1991;7:481–483.
110.
KawakamiMUedaSMaedaT. Vidarabine therapy for virus-associated cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant.1997;20:485–490.
111.
SeabraCPerez-SimonJASierraM. Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic stem cell transplantation. Bone Marrow Transplant.2000;26:1229–1230.
112.
VianelliNRengaMAzziA. Sequential vidarabine infusion in the treatment of polyoma virus-associated acute haemorrhagic cystitis late after allogeneic bone marrow transplantation. Bone Marrow Transplant.2000;25:319–320.
113.
RandKHJohnsonKPRubinsteinLJ. Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: Use of virus-containing cells in the urine to assess response to therapy. Ann Neurol.1977;1:458–462.
114.
BarouchDHFaquinWCChenYKoralnikIJRobbinsGKDavisBT. BK virus-associated hemorrhagic cystitis in a Human Immunodeficiency Virus-infected patient. Clin Infect Dis.2002;35:326–329.
115.
HeldTKBielSSNitscheA. Treatment of BK virus-associated hemorrhagic cystitis and simultaneous CMV reactivation with cidofovir. Bone Marrow Transplant.2000; 26:347–350.
116.
Gonzalez-FraileMICanizoCCaballeroD. Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis. Transpl Infect Dis. March 2001;3:44–46.
117.
GarderetLBittencourtHSebeP. Cystectomy for severe hemorrhagic cystitis in allogeneic stem cell transplant recipients. Transplantation.2000;70:1807–1811.
118.
MarraCMRajicicNBarkerDE. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. Aids.2002;16:1791–1797.
119.
TalmageDAListerudM. Retinoic acid suppresses polyoma virus transformation by inhibiting transcription of the c-fos proto-oncogene. Oncogene.1994;9:3557–3563.
120.
TarabekJZemlaJBacikI. Northern blot hybridization analysis of polyoma virus-specific RNA synthesized under the block of virus replication by 5-bromo-2′-deoxyuridine. Acta Virol.1991;35:305–312.
121.
PortolaniMPietrosemoliPCermelliC. Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase. Antiviral Res.1988;9:205–218.
122.
AtwoodWJ. A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: Implications for prophylactic and therapeutic treatment of progressive multifocal *leuken-cephalopathy. J Neurovirol.2001;7:307–310.
123.
BaumSAshokAGeeG. Early events in the life cycle of JC virus as potential therapeutic targets for the treatment of progressive multifocal leukoencephalopathy. J Neurovirol.2003;9(suppl 1):32–37.
124.
AtwoodWJ. Cellular receptors for the polyomaviruses. In: KhaliliKStonerG, eds. Human Polyomaviruses: Molecular and Clinical Perspectives.New York, NY: Wiley-Liss; 2001:53–72.
125.
ChenYNorkinLC. Extracellular simian virus 40 transmits a signal that promotes virus enclosure within caveolae. Exp Cell Res. January 1999;246:83–90.
126.
GilbertJMGoldbergIGBenjaminTL. Cell penetration and trafficking of polyomavirus. J Virol.2003;77:2615–2622.
127.
AndersonHAChenYNorkinLC. Bound simian virus 40 translocates to caveolin-enriched membrane domains, and its entry is inhibited by drugs that selectively disrupt caveolae. Mol Biol Cell.1996;7:1825–1834.
128.
GeschwindMDSkolaskyRIRoyalWSMcArthurJC. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol.2001;7:353–357.
129.
CheesemanSHBlackPHRubinRHCantellKHirschMS. Interferon and BK Papovavirus—clinical and laboratory studies. J Infect Dis.1980;141:157–161.
130.
KerrDAChangCFGordonJBjornstiMAKhaliliK. Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology.1993;196:612–618.
131.
RoyalW3rdDupontBMcGuireD. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol.2003;9:411–419.
132.
SnoeckRAndreiGLiljaHFitzsimmonsWDeClercqE. Activity of malononitrilamide compounds against murine and simian polyomavirus. Abstract presented at: 5th International Conference on New Trends in Clinical and Experimental Immunosuppression; February 7–10, 2002; Geneva, Switzerland.
133.
CibrikD OTooleJNormanS. IVIG for the treatment of BK nephropathy [abstract 850]. Am J Transplant.2003; 3(suppl 5):370.
134.
FosterPWrightFMcLeanD. Leflunomide administration as an adjunctant in treatment of BK polyoma viral disease in kidney allografts [abstract 1053]. Am J Transplant.2003;3(suppl 5):421.
135.
PoduvalRDKadambiPJavaidB. Leflunomide-a potential new therapeutic agent for BK nephropathy [abstract 144]. Am J Transplant.2003;3(suppl 5):189.
136.
PoduvalRDMeehanSMWoodleES. Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation.2002;73:1166–1169.
137.
Al-JedaiAHHonakerMRTrofeJ. Renal allograft loss as the result of polyomavirus interstitial nephritis after simultaneous kidney-pancreas transplantation: Results with kidney retransplantation. Transplantation.2003;75:490–494.
138.
BoucekPVoskaLSaudekF. Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation.2002;74:1478.
139.
GinevriFPastorinoNDe SantisR. Retransplantation after kidney graft loss due to polyoma BK virus nephropathy: Successful outcome without original allograft nephrectomy. Am J Kidney Dis.2003;42:821–825.
140.
RamosEVincentiFLuWX. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation.2004;77:131–133.
